Form 4: KalVista Pharmaceuticals CEO Benjamin Palleiko Executes Stock Transactions Following Vesting
SEC Form 4 Filing
KalVista Pharmaceuticals CEO Benjamin Palleiko acquired shares through vesting of restricted stock units and performance stock units, and sold a portion to cover tax obligations.
Summary
- KalVista Pharmaceuticals CEO, Benjamin Palleiko, engaged in multiple transactions involving the company's stock.
- On November 17, 2024, Palleiko acquired 30,198 shares of common stock through the vesting of restricted stock units (RSUs) and performance stock units (PSUs).
- On November 18, 2024, Palleiko sold 14,400 shares of common stock at a weighted average price of $9.2565 per share.
- The sale was to cover tax withholding obligations related to the vesting of the RSUs and PSUs and was not a discretionary transaction.
- Following these transactions, Palleiko directly owns 266,598 shares of KalVista common stock.
Sentiment
Score: 5
Explanation: The document reflects routine transactions related to executive compensation and does not indicate any significant positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry where equity-based compensation is prevalent.
Comparison to Industry Standards
- Stock transactions by executives are a common occurrence in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
- The vesting schedules for RSUs and PSUs, such as quarterly vesting, are standard practices for executive compensation.
- The 'sell to cover' transaction to meet tax obligations is a typical method used by executives when vesting equity awards.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they involve the sale of shares by an executive to cover tax obligations.
- The transactions do not have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 11/17/2024 | Date of acquisition of shares through vesting of RSUs and PSUs. |
| 11/18/2024 | Date of sale of shares to cover tax obligations. |
| 11/19/2024 | Date of signature of the Form 4 filing. |
Keywords
KalVista Pharmaceuticals, stock transactions, Form 4, insider trading, Benjamin Palleiko, restricted stock units, performance stock units, vesting, tax obligations, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.